Excessive daytime sleepiness (EDS) is a major source of disability in narcolepsy, idiopathic hypersomnia, residual sleepiness despite CPAP for obstructive sleep apnea, shift work disorder, and various neurologic conditions including Parkinson disease, MS, and post-stroke states. The pharmacology of wakefulness has expanded substantially with the introduction of modafinil/armodafinil, solriamfetol, pitolisant, sodium oxybate, and emerging targeted agents. This page covers stimulants and wake-promoting agents in neurology.

Classification

Stimulants (Sympathomimetic)

  • Increase synaptic dopamine and norepinephrine.
  • Greatest abuse potential.
  • Examples: methylphenidate, amphetamines.

Wakefulness-Promoting Agents (Newer)

  • Different mechanisms; less abuse potential.
  • Modafinil, armodafinil, solriamfetol, pitolisant.

Sleep-Suppressing

  • Sodium oxybate (paradoxical: sedates at night, reduces cataplexy and EDS by day).

Methylphenidate (Ritalin, Concerta)

  • Mechanism: DAT and NET inhibition; increased synaptic DA and NE.
  • Indications: ADHD, narcolepsy.
  • Formulations: IR (Ritalin), ER (Concerta, Ritalin LA, Metadate), patch (Daytrana).
  • Side effects: tachycardia, hypertension, insomnia, appetite suppression, weight loss, tics, anxiety, irritability.
  • Cardiac considerations: avoid in significant CV disease.
  • Schedule II controlled substance.
  • Growth concerns in chronic pediatric use.

Amphetamines

  • Dextroamphetamine (Dexedrine), mixed amphetamine salts (Adderall): DA/NE release + reuptake inhibition.
  • Lisdexamfetamine (Vyvanse): prodrug; lower abuse potential.
  • Methamphetamine: rarely prescribed; high abuse potential.
  • Indications: ADHD, narcolepsy.
  • Side effects: similar to methylphenidate; greater abuse potential.
  • Schedule II.

Modafinil (Provigil)

  • Mechanism: incompletely understood; weak DAT inhibition; activates orexin/hypocretin neurons; modulates histamine.
  • Schedule IV (lower abuse potential than stimulants).
  • Indications: narcolepsy, OSA-related residual EDS, shift work sleep disorder.
  • 100-400 mg daily (typically 200 mg AM).
  • Side effects: headache, nausea, anxiety, insomnia (often dose-related); rare serious rash (SJS); hepatotoxicity (rare).
  • CYP3A4 inducer: reduces OC effectiveness; many interactions.
  • Pregnancy: limited data.

Armodafinil (Nuvigil)

  • R-enantiomer of modafinil.
  • Longer half-life than modafinil.
  • 150-250 mg daily.
  • Similar side effects and interactions.

Solriamfetol (Sunosi)

  • Mechanism: dopamine and norepinephrine reuptake inhibitor (DNRI).
  • FDA-approved 2019 for EDS in OSA and narcolepsy.
  • 75-150 mg daily.
  • Schedule IV.
  • Side effects: headache, nausea, decreased appetite, anxiety, insomnia.
  • Cardiovascular monitoring (BP, HR).
  • Avoid combination with MAOIs.

Pitolisant (Wakix)

  • Mechanism: H3 receptor inverse agonist/antagonist → increases histamine in CNS → promotes wakefulness.
  • FDA-approved 2019 for narcolepsy (EDS and cataplexy).
  • Up-titration to 36 mg daily.
  • NOT a controlled substance.
  • Side effects: headache, insomnia, anxiety, nausea.
  • Interactions: CYP2D6 substrate; sensitive to CYP2D6 inhibitors.
  • Pregnancy: limited data.

Sodium Oxybate (Xyrem, Xywav)

  • γ-hydroxybutyric acid (GHB) salt.
  • Two oral doses at night (HS and 2.5-4 hours later).
  • Mechanism: incompletely understood; GABA-B agonist; consolidates nighttime sleep → reduces cataplexy + daytime sleepiness.
  • Indications: narcolepsy (cataplexy + EDS), idiopathic hypersomnia (Xywav).
  • Xywav (lower-sodium oxybate): alternative for patients needing sodium restriction.
  • REMS program: required (abuse history with GHB).
  • Side effects: nausea, dizziness, sleep disorders, parasomnias, depression.
  • DO NOT combine with alcohol or other CNS depressants.
  • Schedule III.

Specific Conditions

Narcolepsy

Type 1 (with Cataplexy)

  • EDS: modafinil/armodafinil first-line; methylphenidate, amphetamines; sodium oxybate; pitolisant; solriamfetol.
  • Cataplexy: sodium oxybate (gold standard); SSRIs (venlafaxine, fluoxetine); TCAs (older); pitolisant.
  • REM-related symptoms (sleep paralysis, hallucinations): often respond to cataplexy treatments.

Type 2 (without Cataplexy)

  • EDS treatment as above.
  • Cataplexy-specific treatments not needed.

Idiopathic Hypersomnia

  • Modafinil/armodafinil.
  • Clarithromycin (off-label; GABA antagonism hypothesis).
  • Xywav: FDA-approved for IH.

OSA-Related Residual EDS (Despite CPAP)

  • Modafinil, armodafinil: FDA-approved.
  • Solriamfetol: FDA-approved.
  • Confirm CPAP adherence and effectiveness first.

Shift Work Sleep Disorder

  • Modafinil, armodafinil: FDA-approved for SWSD.
  • Strategic napping.
  • Bright light therapy.
  • Melatonin for sleep at non-traditional times.

ADHD

  • Stimulants first-line: methylphenidate, amphetamines.
  • Non-stimulants: atomoxetine (NRI), guanfacine, clonidine, viloxazine.
  • Diagnostic considerations: comprehensive evaluation.

EDS in MS

  • Distinguish fatigue from sleepiness.
  • Amantadine, modafinil for fatigue (off-label for sleepiness).
  • Treat sleep disorders (RLS, OSA, depression).

EDS in PD

  • Optimize dopamine agonist regimen (reduce if “sleep attacks”).
  • Modafinil: limited evidence; sometimes useful.
  • Address underlying sleep disorders.

Post-Stroke Fatigue

  • Methylphenidate: limited evidence; sometimes tried.
  • Treat underlying causes (depression, sleep apnea).

Post-TBI

  • Methylphenidate: emerging evidence for post-TBI cognitive and arousal symptoms.
  • Amantadine: post-coma; emerging.
  • Treat sleep disorders.

Caffeine

  • Mild CNS stimulant; adenosine antagonist.
  • 200-400 mg can be effective.
  • Tolerance with chronic use.
  • Useful for: sleep deprivation, mild fatigue, jet lag (combined with light).
  • Some role in: hypnic headache (paradoxical), post-LP headache.

Drug Interactions and Considerations

  • Modafinil/armodafinil: CYP3A4 inducer → reduces hormonal contraceptive efficacy; counsel.
  • Stimulants + MAOIs: hypertensive crisis; avoid.
  • Solriamfetol + MAOIs: avoid (NE component).
  • Sodium oxybate + alcohol or other CNS depressants: respiratory depression.
  • Pitolisant + CYP2D6 inhibitors: dose adjustment.

Cardiovascular Monitoring

  • Baseline BP and HR.
  • Periodic monitoring.
  • Stimulants: more concerning.
  • Modafinil/solriamfetol: mild BP/HR effects.

Pediatric Considerations

  • Methylphenidate, amphetamines: established for childhood ADHD.
  • Modafinil: not FDA-approved in pediatrics for narcolepsy (off-label use).
  • Growth monitoring.

Pregnancy

  • Limited data on most wake-promoting agents.
  • Behavioral approaches emphasized.
  • Caffeine in moderation OK.

🔍 Did You Know?

The 2019 FDA approvals of pitolisant (Wakix) and solriamfetol (Sunosi) for narcolepsy and OSA-related EDS expanded the wakefulness pharmacopeia with mechanistically novel agents, providing alternatives for patients who fail or cannot tolerate modafinil. Pitolisant — an H3 receptor inverse agonist — increases central histamine release to promote wakefulness, working through an entirely different pathway than stimulants or modafinil. Critically, pitolisant is NOT a controlled substance and has no abuse potential — a significant advantage for patients concerned about controlled substance prescriptions or with substance use history. Solriamfetol — a dopamine and norepinephrine reuptake inhibitor — works through familiar mechanisms but with a distinct safety profile from older stimulants. Both agents have important roles: pitolisant for patients prioritizing non-controlled options and for cataplexy treatment (FDA-approved for both EDS and cataplexy in narcolepsy); solriamfetol for patients who fail modafinil or need an alternative DNRI. The lesson generalizes: mechanistic diversity in pharmacotherapy provides options for patients with treatment failures or specific concerns, and the wakefulness field exemplifies this principle. For practicing neurologists, the take-home: when modafinil fails or is intolerated, pitolisant offers a non-controlled alternative; solriamfetol offers a DNRI with different cardiovascular profile. The wakefulness pharmacology landscape has matured substantially, providing tailored options for diverse patient populations.

Pitfalls and Pearls

  • Methylphenidate, amphetamines: Schedule II; cardiac, growth concerns.
  • Modafinil/armodafinil: Schedule IV; CYP3A4 inducer; reduces OC efficacy.
  • Solriamfetol: DNRI; Schedule IV; cardiovascular monitoring.
  • Pitolisant: H3 inverse agonist; NOT controlled; cataplexy + EDS.
  • Sodium oxybate: REMS; consolidates sleep, reduces cataplexy and EDS.
  • Xywav: lower-sodium oxybate; FDA-approved IH.
  • Narcolepsy + cataplexy: sodium oxybate gold standard; SSRIs/SNRIs for cataplexy alternative.
  • OSA residual EDS: confirm CPAP first; modafinil, armodafinil, solriamfetol.
  • Shift work disorder: modafinil, armodafinil; light, melatonin.
  • ADHD: stimulants first-line; non-stimulants alternatives.
  • Sodium oxybate + alcohol: respiratory depression — counsel.
  • Modafinil reduces OC efficacy: counsel about alternative contraception.
  • Avoid in narcolepsy treatment: long-acting benzodiazepines worsen EDS.
  • EDS in MS: distinguish from fatigue.
  • PD sleep attacks: reduce dopamine agonist.
  • Caffeine: mild stimulant; useful adjunct.

References

  1. Krahn LE, Hershner S, Loeding LD, et al. Quality measures for the care of patients with narcolepsy. J Clin Sleep Med. 2015;11(3):335-355.
  2. Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020;68:97-109.
  3. Strollo PJ, Stepanski EJ, Black J, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019;155(2):364-374.
  4. Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068-1075.
  5. Mignot E. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739-752.